Global News

Viveve announces positive topline results For VIVEVE I clinical trial

Tuesday, April 26, 2016

Viveve Medical, a company focused on women’s health, has announced positive top-line results from the VIVEVE I clinical study. The VIveve Treatment of the Vaginal Introitus to EValuate Efficacy study is the first randomized, single-blinded and sham-controlled trial designed to demonstrate the efficacy and safety of the Viveve Treatment versus a sham control procedure for the treatment of vaginal introital laxity.

[Read More]

MSOAC launches database for MS clinical trial data

Tuesday, April 26, 2016

A new database containing nearly 2500 patient records from the placebo arms of nine multiple sclerosis (MS) clinical trials is now available for research by qualified investigators. This is just one of the tools generated through the Multiple Sclerosis Outcome Assessments Consortium (MSOAC), a global effort launched by the National MS Society and Critical Path Institute (C-Path). MSOAC is striving to develop an outcomes measure that addresses the critical need for a more sensitive way to detect the benefit of potential treatments that slow or reverse progressive disability in people with MS.

[Read More]

Valeant names Joseph C. Papa chairman, CEO

Tuesday, April 26, 2016

Valeant Pharmaceuticals International has named Joseph C. Papa to become Valeant’s chairman and chief executive officer. Papa is expected to join Valeant by early May. Papa will join Valeant from Perrigo company, a global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and prescription (Rx) pharmaceuticals, where he served as chairman and chief executive officer. Papa, who will also join Valeant’s board of directors, will succeed J. Michael Pearson, who is expected to remain as CEO and a director until Papa arrives at Valeant.

[Read More]

Daiichi Sankyo to open new U.S. headquarters in New Jersey

Tuesday, April 26, 2016

Daiichi Sankyo, Inc., the U.S. subsidiary of Daiichi Sankyo Company, Ltd., will establish a new U.S. headquarters, co-locating its commercial and development divisions in Basking Ridge, New Jersey. The move is part of an ongoing effort to realize efficiencies and continue collaboration between the business segments, enabling innovation in its existing and emerging therapeutic areas such as cardiology, oncology, pain and other areas where there are unmet medical needs.

[Read More]

BePATIENT, Vital Connect launch BeVITAL

Tuesday, April 26, 2016

Vital Connect, a provider of design and deployment of wearable biosensor technologies, and BePATIENT, a startup that develops patient-centric digital health solutions, has announced the first North American deployment of BeVITAL. The remote patient monitoring solution combines VitalConnect’s FDA-cleared biosensor, HealthPatch MD, with BePATIENT’s web-based solution and associated app, which allows the implementation of personalized healthcare programs accessible through mobile devices and computers.

[Read More]

Bracket launches patient engagement tools for eCOA, RTSM

Monday, April 25, 2016

Bracket, a clinical trial specialty services provider, has announced platform updates to Bracket eCOA and Bracket RTSM to include native support for SMS messaging with patients and other stakeholders in clinical research programs. This important update expands the medication compliance and adherence functionality across Bracket’s eClinical portfolio, and provides an effective solution for supporting patients participating in clinical trials.

[Read More]

Quintiles receives technology security award from CSO Magazine

Monday, April 25, 2016

Quintiles, a provider of biopharmaceutical services, has been named to the 2016 CSO50 by IDG’s CSO magazine. This award recognizes the company’s innovative identity management solution designed to expedite activities related to the delivery of clinical trials while simultaneously protecting confidential user data. This is the company’s fourth consecutive year receiving the security award.

[Read More]

Allergan acquires Topokine Therapeutics for fat reduction development program

Monday, April 25, 2016

Allergan, a global pharmaceutical company, has acquired Topokine Therapeutics, a privately held, clinical-stage biotechnology company focused on developing topical medicines for fat reduction. Allergan acquired Topokine Therapeutics for an upfront payment of $85 million and success-based development and sales milestones for XAF5, a first-in-class topical agent in late-stage development for the treatment of steatoblepharon, also known as undereye bags.

[Read More]